ChromaDex Corporation Reports Third Quarter 2020 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales of $14.2 million, up 18% from $12.1 million from the year ago quarter. Tru Niagen® net sales of $11.9 million, a 22% increase from the year ago quarter. Net loss was ($4.2) million or ($0.07) per share, an improvement of $0.05 per share year-over-year. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of
